Prof Garbe talks to ecancertv at EADO 2015 about how and when to combine immunotherapy and targeted therapies to treat melanoma.
Should we use Anti-PD-1 or anti-CTLA-4 in first line therapy?
ecancer's filming at EADO 2015 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
![](https://s2.save4k.ru/pic/8texTM2G95g/maxresdefault.jpg)